Progenics Pharmaceuticals (PGNX) 8-K Submission of Matters to a Vote of Security Holders

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)June 14, 2017

Progenics Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

Delaware	000-23143	13-3379479
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)
One World Trade Center, New York, New York		10007
(Address of principal executive offices)		(Zip Code)
Registrant's telephone number, including area code(646)975-2500

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (seeGeneral Instruction A.2. below):

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.07.             Submission of Matters to a Vote of Security Holders.

At the Annual Meeting of Progenics Pharmaceuticals, Inc. (the “Company”) held on June 14, 2017, stockholders voted on the following matters set forth below.

1. The nominees for election to the Company’s Board of Directors were elected to hold office until the Company’s next Annual Meeting of Stockholders, based upon the following votes:

Nominees	Votes For		Votes Against		Abstentions		Broker Non-Votes
Peter J. Crowley		47,676,068		484,725		24,799		15,820,499
Mark R. Baker		47,769,866		379,723		36,003		15,820,499
Bradley L. Campbell		47,659,957		487,889		37,746		15,820,499
Karen J. Ferrante		47,671,270		489,632		24,690		15,820,499
Michael D. Kishbauch		47,664,304		495,989		25,299		15,820,499
David A. Scheinberg		47,669,016		490,034		26,542		15,820,499
Nicole S. Williams		47,667,033		493,681		24,878		15,820,499

2. The proposal to approve, on an advisory basis, the compensation of the Company’s Named Executive Officers was approved, based upon the following votes:

Votes For Approval	Votes Against		Abstentions		Broker Non-Votes
47,655,721		475,452		54,419		15,820,499

3. The proposal on the frequency of future advisory votes on compensation of named executive officers was recommended, on an advisory basis, based upon the following votes:

1 Year	2 Years		3 Years		Abstentions
42,385,958		22,224		5,735,244		42,166

4. The proposal to ratify the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the 2017 fiscal year was approved, based upon the following votes:

Votes For Approval	Votes Against		Abstentions		Broker Non-Votes
63,784,834		120,502		100,755		-

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PROGENICS PHARMACEUTICALS, INC.
By:	/s/Patrick Fabbio
	Patrick Fabbio
	Senior Vice President and Chief Financial Officer

Date: June 15, 2017